share_log

Following The Announcement By Asahi Kasei That It Controls Over 90% Of Calliditas Therapeutics Has Resolved To Apply For Delisting Its Common Shares From Nasdaq Stockholm And Its American Depositary Shares From The Nasdaq Global Select Market

Benzinga ·  Sep 3 18:42
Following The Announcement By Asahi Kasei That It Controls Over 90% Of Calliditas Therapeutics Has Resolved To Apply For Delisting Its Common Shares From Nasdaq Stockholm And Its American Depositary Shares From The Nasdaq Global Select Market
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment